In both cohorts, high expression of PGRMC1 significantly predicted the shorter overall survival of GBM patients (Hannover cohort: HR = 1.532, CI [95%] = 1.042–2.253, p = 0.030; Magdeburg cohort: HR = 1.462, CI [95%] = 1.039–2.057, p = 0.029) (Figure 1E). Here, PGRMC1 is linked to glioblastoma.